-- Vir Biotechnology and GlaxoSmithKline's investigational SARS-CoV-2 antibody, engineered with the Xencor XmAb ® Fc technology, Xtend™, is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients -- -- Treatment with sotrovimab resulted in an 85% reduction

Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement (BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three

-- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Xencor, Inc.

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc.

MONROVIA, Calif. --(BUSINESS WIRE)--May 25, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement

Xencor and Chugai Initiate Partnership for Optimized Antibodies Chugai licenses Xencor’s XmAb™ technology to enhance antibody efficacy Monrovia, CA – January 10, 2005 – Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd.

Xencor and CSL Limited Establish Antibody Optimization Collaboration Monrovia, CA – February 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd.

Genentech licenses Xencor’s XmAb™ technology for CD20 and Her2, key cancer and autoimmune targets

MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology

MONROVIA, Calif. & HOUSTON --(BUSINESS WIRE)--Sep. 3, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced